Lymphocyte Activation
Research News and Information

Sunday, November 22, 2009

TLR9 activation increases TAP-independent vesicular MHC class I processing in vivo.

30 Oct 2009 Cross-presentation of soluble protein antigens on major histocompatibility complex (MHC) class I by dendritic cells (DC) can occur in vesicular, endolysosomal compartments and be either dependent or independent of TAP peptide transporters. Here we ... Read more...

Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response.

30 Oct 2009 A novel assay to assess antigen-specific cytokine release from stimulated CD8(+) T cells derived from the mucosal and peripheral blood compartments has been developed and standardized using the influenza A virus matrix protein (MP) peptide, ... Read more...

The cellular and molecular immune response of the weanling piglet to staphylococcal enterotoxin B.

30 Oct 2009 Staphylococcal enterotoxin B (SEB) is a biothreat agent, etiologic agent of food poisoning, and potent inducer of toxic shock syndrome. This heat-stable exoprotein is thought to act as a superantigen to induce T cell-specific pathology. Most animal ... Read more...

Latest indexed articles for 'Lymphocyte Activation'

These are the very latest articles for this heading:

• TLR9 activation increases TAP-independent vesicular MHC class I processing in vivo. 30 Oct 2009
• Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response. 30 Oct 2009
• The cellular and molecular immune response of the weanling piglet to staphylococcal enterotoxin B. 30 Oct 2009
• The effects of electroacupuncture on TH1/TH2 cytokine mRNA expression and mitogen-activated protein kinase signaling pathways in the splenic T cells of traumatized rats. 30 Oct 2009
• The effect of perioperative intravenous lidocaine on postoperative pain and immune function. 30 Oct 2009
• Regulatory T-cells in periapical lesions. 30 Oct 2009
• Positively selecting peptides: their job does not end in the thymus. 30 Oct 2009
• Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. 30 Oct 2009
• KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. 24 Oct 2009
• Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. 17 Oct 2009
• Cutting Edge: Responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B. 13 Oct 2009
• Cutting Edge: Importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes. 13 Oct 2009
• Porphyromonas gingivalis fimbriae induce unique dendritic cell subsets via Toll-like receptor 2. 5 Oct 2009
• T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. 4 Oct 2009
• CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. 3 Oct 2009
• An endogenous peptide positively selects and augments the activation and survival of peripheral CD4+ T cells. 2 Oct 2009
• An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. 2 Oct 2009
• Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. 29 Sep 2009
• Antigen-dependent rescue of nose-associated lymphoid tissue (NALT) development independent of LTbetaR and CXCR5 signaling. 29 Sep 2009
• Concurrent infection with Heligmosomoides polygyrus suppresses anti-Plasmodium yoelii protection partially by induction of CD4(+)CD25(+)Foxp3(+) Treg in mice. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Lymphocyte Activation'

Definition: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific antigens. It may also occur in vivo as in GRAFT REJECTION.

Descriptor UI: D008213

Alternative terms: Lymphocyte Activation; Activation, Lymphocyte; Blastogenesis; Lymphoblast Transformation; Lymphocyte Stimulation; Stimulation, Lymphocyte; Transformation, Lymphocyte; Transformation, Blast; Transformation, Lymphoblast; Blast Transformation; Lymphocyte Transformation;

Related Mesh Headings: Blast Crisis;

Allowable Qualifiers: drug effects; genetics; immunology; physiology; radiation effects;

Tree Number: E01.450.495.482; E05.478.594.530; G12.425.747; G12.450.555.545;

History Note: 2003 (1969); for BLAST TRANSFORMATION use BLAST CRISIS 1987-1992

Technical Notes: lymphocyte transformation test goes here but do not index under specific agent inducing transformation unless particularly discussed; do not use for neoplastic transformation of lymphocytes ( = CELL TRANSFORMATION, NEOPLASTIC) or viral transformation of lymphocytes ( = CELL TRANSFORMATION, VIRAL); blast transformation in chronic myelogenous leukemia does not go here: index BLAST CRISIS; DF: LYMPHOCYTE TRANSFORM